The current financial score of Trinity Biotech PLC is 6.22. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 10.85M, representing a year-over-year increase of 43.28%, while its net profit experienced a year-over-year increase of 50.04%.
The current valuation score of Trinity Biotech PLC is 9.80. Its current P/E ratio is -1.18, which is -95.06% below the recent high of -0.06 and -121.52% above the recent low of -2.60.
No earnings forecast score is currently available for Trinity Biotech PLC. The Healthcare Equipment & Supplies industry's average is 7.80.
The current price momentum score of Trinity Biotech PLC is 6.96. Currently, the stock price is trading between the resistance level at 7.68 and the support level at 4.70, making it suitable for range-bound swing trading.
The current institutional shareholding score of Trinity Biotech PLC is 3.00. The latest institutional shareholding proportion is 4.33%, representing a quarter-over-quarter decrease of 93.02%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.
The current risk assessment score of Trinity Biotech PLC is 1.53. The company's beta value is 0.92. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.